RU2007112114A - Применение селективного модулятора эстрогеновых рецептов для получения фармацевтического препарата для применения в способе лечения или профилактики андрогенной недостаточности - Google Patents

Применение селективного модулятора эстрогеновых рецептов для получения фармацевтического препарата для применения в способе лечения или профилактики андрогенной недостаточности Download PDF

Info

Publication number
RU2007112114A
RU2007112114A RU2007112114/15A RU2007112114A RU2007112114A RU 2007112114 A RU2007112114 A RU 2007112114A RU 2007112114/15 A RU2007112114/15 A RU 2007112114/15A RU 2007112114 A RU2007112114 A RU 2007112114A RU 2007112114 A RU2007112114 A RU 2007112114A
Authority
RU
Russia
Prior art keywords
enyl
chloro
hydroxyethoxy
metabolite
isomer
Prior art date
Application number
RU2007112114/15A
Other languages
English (en)
Russian (ru)
Inventor
Тару БЛОМ (FI)
Тару БЛОМ
Янне КОМИ (FI)
Янне КОМИ
Ристо ЛАММИНТАУСТА (FI)
Ристо ЛАММИНТАУСТА
Original Assignee
Хормос Медикал Лтд. (Fi)
Хормос Медикал Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/fi
Application filed by Хормос Медикал Лтд. (Fi), Хормос Медикал Лтд. filed Critical Хормос Медикал Лтд. (Fi)
Publication of RU2007112114A publication Critical patent/RU2007112114A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007112114/15A 2004-09-03 2005-07-20 Применение селективного модулятора эстрогеновых рецептов для получения фармацевтического препарата для применения в способе лечения или профилактики андрогенной недостаточности RU2007112114A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
US60/606,907 2004-09-03
FI20041216 2004-09-21
FI20041216A FI20041216A0 (fi) 2004-09-21 2004-09-21 Menetelmä androgeenivajeen hoitoon tai estoon

Publications (1)

Publication Number Publication Date
RU2007112114A true RU2007112114A (ru) 2008-10-10

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007112114/15A RU2007112114A (ru) 2004-09-03 2005-07-20 Применение селективного модулятора эстрогеновых рецептов для получения фармацевтического препарата для применения в способе лечения или профилактики андрогенной недостаточности

Country Status (10)

Country Link
EP (1) EP1786408A4 (de)
JP (1) JP2008511615A (de)
KR (1) KR20070059110A (de)
AU (1) AU2005279178A1 (de)
BR (1) BRPI0514701A (de)
CA (1) CA2578852A1 (de)
MX (1) MX2007002606A (de)
NO (1) NO20071160L (de)
RU (1) RU2007112114A (de)
WO (1) WO2006024689A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2121553T1 (sl) 2007-02-14 2012-11-30 Hormos Medical Ltd Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
US20080312239A1 (en) * 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3240771B1 (de) 2014-12-29 2019-02-20 OLON S.p.A. Verfahren zur herstellung von ospemifen und fispemifen
WO2023175010A1 (fr) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Utilisation du bazedoxifene pour augmenter la survie musculaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CA2409647C (en) * 2000-05-26 2012-07-03 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
EP1574212A1 (de) * 2001-11-29 2005-09-14 GTX Inc. Vorbeugung und Behandlung von durch Androgenmangel induzierten Erkrankungen

Also Published As

Publication number Publication date
CA2578852A1 (en) 2006-03-09
NO20071160L (no) 2007-05-25
WO2006024689A1 (en) 2006-03-09
MX2007002606A (es) 2007-05-15
EP1786408A1 (de) 2007-05-23
JP2008511615A (ja) 2008-04-17
AU2005279178A1 (en) 2006-03-09
EP1786408A4 (de) 2010-07-28
KR20070059110A (ko) 2007-06-11
BRPI0514701A (pt) 2008-06-24

Similar Documents

Publication Publication Date Title
RU2007112114A (ru) Применение селективного модулятора эстрогеновых рецептов для получения фармацевтического препарата для применения в способе лечения или профилактики андрогенной недостаточности
KR100767317B1 (ko) 선택적 안드로겐 수용체 조절자를 이용한 근소모 치료방법
JP7221699B2 (ja) Ａｒ＋乳癌の治療方法
EP1753417B1 (de) Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
TW200413288A (en) Treating obesity with selective androgen receptor modulators
JP2004507465A5 (de)
JP2005526741A5 (de)
RU2006140962A (ru) Новые фармацевтические композиции для лечения сексуальных расстройств
JP2012518661A5 (de)
JP2011507843A5 (de)
JP2021046448A (ja) 癌療法における使用のためのトランス−クロミフェン
US20200113863A1 (en) Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases
JP2003528057A (ja) 抗エストロゲン作用を有する４−フルオルアルキル−２ｈ−ベンゾピラン
CZ20002205A3 (cs) Hydrát soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidin-2,4-dionu s kyselinou maleinovou
DK2155180T3 (en) Medicament combination and its use for the treatment of muscle wasting
CN1658904A (zh) 包含埃坡霉素的组合及其药学用途
CN1893955A (zh) 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物
CN1072411A (zh) 用于治疗的新的活性化合物
JPWO2004013104A1 (ja) 新規テトラヒドロキノリン誘導体
RU2001132596A (ru) Трехъядерные конденсированные гетероциклические соединения, способ их получения (варианты и фармацевтическая композиция)
JPWO2021129653A5 (de)
CN1791404A (zh) 抗关节炎组合物
Hajela et al. Non steroidal estrogen antagonists: current status and future perspectives
MX2007004575A (es) Metodos para usar esteres de acidos grasos de estrogenos y compuestos que inhiben la reasimilacion de serotonina para reducir el peso corporal de un mamifero y composicioens que contienen los mismos.
CN1653083A (zh) 治疗门和肝静脉循环急性功能紊乱的脱氧胆酸衍生物

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100504